RAGE antagonist peptide 是一种晚期糖基化终产物 (RAGE) 拮抗剂。RAGE antagonist peptide (RAP) 可阻断 RAGE 和几个重要配体 HMGB-1、S100P、S100A4 的结合。RAGE antagonist peptide (RAP) 具有抗肿瘤和抗炎活性。
| 生物活性 | RAGE antagonist peptide is an advanced glycation end products (RAGE) antagonist. RAGE antagonist peptide prevents RAGE from binding with several of its most important ligands, including HMGB-1, S100P, and S100A4. RAGE antagonist peptide (RAP) possesses anti-tumor and anti-inflammatory activities[1][2]. |
体外研究
(In Vitro) | RAGE antagonist peptide (RAP) reduces the ability of the ligands to stimulate RAGE activation of NFκB in cancer cells in vitro[1].
|
体内研究
(In Vivo) | RAGE antagonist peptide (RAP, 100 μg) inhibits RAGE-mediated Basal NFκB Activity in PDAC cells in vivo[1].
RAGE antagonist peptide (RAP) reduces the growth and metastasis of pancreatic tumors and also inhibited glioma tumor growth[1].
In mice bearing asthma, RAGE antagonist peptide (RAP; 4 mg/kg; i.p.) blunts airway reactivity, airway inflammation and goblet cell metaplasia, and decreases release of Th2 cytokines. RAGE antagonist peptide also reduces total, cytoplasmic and nuclear levels of β-catenin, enhanced β-catenin phosphorylation at Ser33/37/Thr41, which triggers ubiquitination, down-regulated expression of β-catenin targeted genes, and tends to keep β-catenin at the cytomembrane, shifting β-catenin from a signalling active pattern to an adhesive function[2].
| Animal Model: | Cancer cells expressing the NFκB-luc reporter implanted into immune-deficient mice[1]. | | Dosage: | 100 μg. | | Administration: | Intratumoral delivery (or intraperitoneally). | | Result: | Systemic administration caused a substantial reduction (p<0.05) in the NFκB signal 5 h after injection. |
|
| 分子量 | |
| Formula | |
| CAS 号 | |
| Sequence Shortening | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com